These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34584637)

  • 1. MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types.
    Wu SY; Lin KC; Lawal B; Wu ATH; Wu CZ
    Comput Struct Biotechnol J; 2021; 19():4970-4983. PubMed ID: 34584637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.
    Dai L; Tao Y; Shi Z; Liang W; Hu W; Xing Z; Zhou S; Guo X; Fu X; Wang X
    Front Oncol; 2022; 12():881801. PubMed ID: 35600392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis.
    Zhang X; He X; Li Y; Xu Y; Chen W; Liu X; Hu X; Xiong L; Xu X
    Front Mol Biosci; 2021; 8():702206. PubMed ID: 34859046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of MAX dimerization protein 3 (MXD3) predicts poor prognosis in clear cell renal cell carcinoma.
    Zhang F; Liu L; Wu P; Li S; Wei D
    Transl Androl Urol; 2021 Feb; 10(2):785-796. PubMed ID: 33718080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.
    Guo X; Zhou L; Wu Y; Li J
    Oxid Med Cell Longev; 2022; 2022():2764940. PubMed ID: 36742345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the shared gene MXD3 signatures and biological mechanism in patients with hip pain and prostate cancer.
    Huang L; Xie Y; Jiang S; Gong B; Feng Y; Shan H
    Medicine (Baltimore); 2024 Sep; 103(37):e39592. PubMed ID: 39287260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis of the prognostic and immunological role of ANLN: An onco-immunological biomarker.
    Liu K; Cui L; Li C; Tang C; Niu Y; Hao J; Bu Y; Chen B
    Front Genet; 2022; 13():922472. PubMed ID: 35991576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 9. A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective.
    Bao H; Luo Y; Ding G; Fu Z
    J Oncol; 2022; 2022():3982539. PubMed ID: 35578600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC01614 is a promising diagnostic and prognostic marker in HNSC linked to the tumor microenvironment and oncogenic function.
    Tian X; Hu D; Wang N; Zhang L; Wang X
    Front Genet; 2024; 15():1337525. PubMed ID: 38655053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Splicing of MXD3 and Its Regulation of MXD3 Levels in Glioblastoma.
    Ngo T; Corrales A; Bourne T; Elmojahid S; Lam KS; Díaz E
    Front Mol Biosci; 2019; 6():5. PubMed ID: 30838212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of
    Yeh YC; Lawal B; Hsiao M; Huang TH; Huang CF
    Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis based on epigenetic modification explains the value of HJURP in the tumor microenvironment.
    Li J; Zheng J; Zhang R; Zhang W; Zhang J; Zhang Y
    Sci Rep; 2022 Dec; 12(1):20871. PubMed ID: 36460821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrated Analysis of the Identified PRPF19 as an Onco-immunological Biomarker Encompassing the Tumor Microenvironment, Disease Progression, and Prognoses in Hepatocellular Carcinoma.
    Yang M; Qiu Y; Yang Y; Wang W
    Front Cell Dev Biol; 2022; 10():840010. PubMed ID: 35252202
    [No Abstract]   [Full Text] [Related]  

  • 15. MXD3 regulation of DAOY cell proliferation dictated by time course of activation.
    Ngo T; Barisone GA; Lam KS; Dίaz E
    BMC Cell Biol; 2014 Jul; 15():30. PubMed ID: 25053245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and verification of YBX3 and its regulatory gene HEIH as an oncogenic system: A multidimensional analysis in colon cancer.
    Sun Y; Li Z; Wang W; Zhang X; Li W; Du G; Yin J; Xiao W; Yang H
    Front Immunol; 2022; 13():957865. PubMed ID: 36059530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis on the Oncogenic Role of Programmed Cell Death 10.
    Sun N; Li C; Teng Y; Deng Y; Shi L
    J Oncol; 2022; 2022():1242658. PubMed ID: 36276268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance.
    Lawal B; Tseng SH; Olugbodi JO; Iamsaard S; Ilesanmi OB; Mahmoud MH; Ahmed SH; Batiha GE; Wu ATH
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.